IP Library Granted Patent US 11,077,071
Granted Patent B2
US 11,077,071 · App. 16/043,582 · Granted Aug 3, 2021

Phytonadione compositions and related methods

Inventors: Phanesh Koneru (Lenoir, NC); Sreerarama Murthy Mallipeddi (Lenoir, NC); Jonathan E. Sterling (Lenoir, NC)
Assignee: Exela Holdings, Inc.
A61K31/122A61J1/05A61K9/0019A61K47/26A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,077,071
App. No.
16/043,582
Granted
Aug 3, 2021
Kind
B2
Abstract

Stable Phytonadione compositions for parenteral administration are provided which comprise (E) isomer of phytonadione at or greater than 97% w/w as the active ingredient, and is substantially free of (Z) isomer. Said compositions are stable, sterile, and particulate-free. Further, said compositions reduce or avoid allergic reactions to benzyl alcohol and polysorbate. In some aspects, the compositions are free or substantially free of benzyl alcohol and/or reduced amounts of polysorbate. Methods of manufacture and methods of administration also provided.

Claims (15)

1. A stable, injectable, sterile, particulate-matter-free, aqueous phytonadione composition comprising Phytonadione in its (E) isomer form that has less than or equal to 3% w/w of its (Z) isomer, at a concentration of from about 100 ug/ml to about 20 mg/ml;

and is free of benzyl alcohol.

2. The composition of claim 1 , wherein said (Z) isomer is present from 0.5% to less than or equal to 3% w/w of the (E) isomer.

3. The composition of claim 1 , wherein said composition is free of cremophor.

4. The composition of claim 1 , wherein said composition is free of propylene glycol.

5. The composition of claim 1 , wherein the composition comprises less than 1:10 ratio of (E)-isomer of phytonadione:

polysorbate.

6. The composition of claim 1 , wherein said composition is provided in a non-reacting glass or non-reacting polymeric container selected from a vial container or a pre-filled syringe container.

7. The composition of claim 6 , wherein the non-reacting polymeric container is made of polyethylene or polypropylene or a combination thereof.

8. The composition of claim 1 , wherein an epoxide derivative of the (E) isomer of phytonadione is present at less than 4% w/w of the (E) isomer.

9. A method comprising: administering the composition of claim 1 to a mammal.

10. The method of claim 9 , wherein the mammal is a human.

11. A method of reducing an anaphylactic reaction associated with phytonadione administration comprising:

administering a composition comprising Phytonadione in its (E) isomer form that is substantially free of its (Z) isomer, at a concentration of from about 0.1 mg/ml to about 20 mg/ml; and optionally a pH adjuster, wherein the composition has a pH of from about 3.5 to about 8.0, wherein said (Z) isomer is present at about 3% w/w or less of the (E) isomer; and wherein said composition is free of benzyl alcohol and cremophor, and comprises a polysorbate at a concentration of less than about 1:10 ratio of (E) isomer of phytonadione: polysorbate.

12. The method of claim 11 , wherein the composition is administered from a vial or a pre-filled syringe wherein the vial or pre-filled syringe is selected from a non-reacting glass or polymeric material.

Assignments (4)
SECURITY INTEREST Recorded Jun 30, 2021
From: EXELA HOLDINGS, INC.; EXELA PHARMA SCIENCES, LLC; EXELA PHARMSCI, INC.; EXELA STERILE MEDICINES LLC; EXELA STERILE PRODUCTS LLC; EXELA STERILE EQUIPMENT, LLC; EXELA ADVANCED STRATEGIES LLC; AGELEX, LLC; EXELA HEALTH SYSTEMS, LLC; EXELA INITIATIVES, LLC; EXELA INNOVATIONS, LLC
To: LIVE OAK BANKING COMPANY
Reel/Frame 056722/0188 →
SECURITY INTEREST Recorded Jun 30, 2021
From: EXELA HOLDINGS, INC.; EXELA PHARMA SCIENCES, LLC; EXELA PHARMSCI, INC.; EXELA STERILE MEDICINES LLC; EXELA STERILE PRODUCTS LLC; EXELA STERILE EQUIPMENT, LLC; EXELA ADVANCED STRATEGIES LLC; AGELEX, LLC; EXELA HEALTH SYSTEMS, LLC; EXELA INITIATIVES, LLC; EXELA INNOVATIONS, LLC
To: LIVE OAK BANKING COMPANY
Reel/Frame 056722/0250 →
SECURITY INTEREST Recorded Oct 1, 2019
From: EXELA HOLDINGS, INC.
To: DEERFIELD PRIVATE DESIGN FUND IV, L.P., AS COLLATERAL AGENT
Reel/Frame 050581/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2018
From: KONERU, PHANESH; MALLIPEDDI, SREERARAMA MURTHY; STERLING, JONATHAN E.
To: EXELA HOLDINGS, INC
Reel/Frame 046496/0884 →
Continuity (3)
Continuation 15054797 · Feb 26, 2016
Provisional Application 62121869 · Feb 27, 2015
Related Publication 20180325843A1 · Nov 15, 2018